Session » (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 0483

The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)

Abstract Number: 0484

Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study

Abstract Number: 0485

Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial

Abstract Number: 0486

Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity

Abstract Number: 0487

A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis

Abstract Number: 0488

Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity

Abstract Number: 0489

Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study

Abstract Number: 0490

Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team

Abstract Number: 0491

Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound

Abstract Number: 0492

Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?

Abstract Number: 0493

Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque

Abstract Number: 0494

Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque

Abstract Number: 0495

Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study

Abstract Number: 0496

Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis

Abstract Number: 0497

Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis

Abstract Number: 0498

Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)

Abstract Number: 0499

Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry

Abstract Number: 0500

Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention

Abstract Number: 0501

Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis

Abstract Number: 0502

Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients

Abstract Number: 0503

Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging

Abstract Number: 0504

Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature

Abstract Number: 0505

Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study

Abstract Number: 0506

Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study

Abstract Number: 0507

The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis

Abstract Number: 0508

Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

Abstract Number: 0509

Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.